Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. - Wikidata - awgldk - TriplyDB

Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.

Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.

http://www.wikidata.org/entity/Q33573450

about

Immunotherapy for cancer in the central nervous system: Current and future directions Cancer immunotherapy: the beginning of the end of cancer?Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium Immune checkpoint inhibitors: therapeutic advances in melanoma Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites Reflections on the Histopathology of Tumor-Infiltrating Lymphocytes in Melanoma and the Host Immune Response Modulation of GITR for cancer immunotherapy Treg functional stability and its responsiveness to the microenvironment A series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potency Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma Cancer immunotherapy comes of age The "Trojan Horse" approach to tumor immunotherapy: targeting the tumor microenvironment.GITR ligand fusion protein agonist enhances the tumor antigen-specific CD8 T-cell response and leads to long-lasting memory.Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity.Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.Systemic CD8+ T cell-mediated tumoricidal effects by intratumoral treatment of oncolytic herpes simplex virus with the agonistic monoclonal antibody for murine glucocorticoid-induced tumor necrosis factor receptor.Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability.Expansion of regulatory GITR+CD25 low/-CD4+ T cells in systemic lupus erythematosus patients.Up-regulation of GITRL on dendritic cells by WGP improves anti-tumor immunity in murine Lewis lung carcinoma.Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells.Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens.Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer.Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy.Agonist antibodies to TNFR molecules that costimulate T and NK cells Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates.The status, limitation and improvement of adoptive cellular immunotherapy in advanced urologic malignancies Glucocorticoid-induced tumour necrosis factor receptor-related protein: a key marker of functional regulatory T cells.Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.Recent developments on immunotherapy for brain cancer.Th2 responses to helminth parasites can be therapeutically enhanced by, but are not dependent upon, GITR-GITR ligand costimulation in vivo.Pharmacological modulation of GITRL/GITR system: therapeutic perspectives.Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells ex vivo.IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival Rheumatoid Fibroblast-like Synoviocytes Downregulate Foxp3 Expression by Regulatory T Cells Via GITRL/GITR Interaction The role of checkpoints in the treatment of GBM Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma.Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication.

P2860

Q26750765-54FE0D9E-2EDD-43F9-90EB-262F8F153C25 Q26752277-D289E50E-475A-40E3-AB5B-0E5653B86C46 Q26765459-62C70D52-236C-4609-825B-C7574F98CDDC Q26775591-CA37CEFE-F069-42B9-95AE-59815AF6E80B Q26798402-BD739EC0-F72E-418E-BD94-86E1C998F1E4 Q26799073-128B5649-F177-444C-BF97-C3AA15D02650 Q26853557-E9215C84-A68D-4A3F-A890-AAF657FF04FC Q27008946-02BC0599-7C60-4918-B7C0-24E220DB4C7A Q27676800-6D9998C5-5453-477F-8606-8984413D7BDE Q28071998-0BE814A4-405A-430A-9AA7-567AC818706A Q29619918-A20B37CF-28D5-40D6-A3D8-D37983F1E4A0 Q33736218-376DDC83-9A14-49A6-9815-2E4F64DE8586 Q33814776-79B07389-1E91-4D89-AFEF-DE1956A2EDDF Q33889105-1F07D07E-8841-4429-A917-3106DAF1B999 Q33926200-44F35544-6492-45B5-9C25-0CC7020E5242 Q34020594-88FABF0F-EA30-4972-A640-C7A035422632 Q34276759-3AD303F6-EFC4-44FE-B017-E6B0D5BABBCF Q34397451-42527CAE-45C8-408C-B1F4-0CB4A5F63B0E Q34401977-741E8623-1111-4164-9735-D3F97D32DB64 Q34450476-AAAC4E30-6317-4A19-9072-918A3CD49EFF Q34633278-AED06DD8-7A8A-406A-8EF1-7E0EFE42FD73 Q34634220-7907435D-3DF4-42E6-9216-66054FDA7077 Q35051508-CBB01B3F-2646-43E3-BE52-7C6577875433 Q35289145-CFA7BA3E-5183-46F7-AAC1-D16E1573787D Q35294382-AB88CA76-AE14-4295-9EBE-A651035B1F12 Q35427446-0577BEDD-AB88-4378-A20F-FAF45DBF4B79 Q35527105-1FBDD99D-7953-4A28-8CA8-15E948794390 Q35538728-133D59BA-BEB3-4215-B0E4-EAF2C0BC0096 Q35551328-D9060AC0-14D5-435F-9B88-5F3F6D3EAED9 Q35753251-77509B40-1842-4DE3-ABC7-33AE1174283D Q35992355-F4A16770-9E9E-4B9A-9270-085B0DB7C138 Q36124241-9B241638-6713-4F15-B96F-93E36F04FCBC Q36147260-7A80B0D6-8279-4B60-BAD2-F15FA4BF97AE Q36203023-F037C7C8-0721-4083-A2A3-B8CEF9E58363 Q36256549-E732C4EB-2A31-41F0-A8D7-68276393C58F Q36405905-4C77FA02-81FE-4A0B-92D8-DD9F63C0B023 Q36431028-58DFDFF6-4166-4E36-896E-2BE54209A270 Q36571197-AE153ADF-7FDD-4018-AD81-6CE62613FB84 Q36907372-B65EDCD5-11FE-42B7-A337-87AF0775700E Q37055402-A9A54CC4-32FB-42F3-871D-7E7CC22A4CED

P2860

Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.

http://www.wikidata.org/entity/Q33573450

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Agonist anti-GITR monoclonal a ...... and intra-tumor accumulation.

@ast

Agonist anti-GITR monoclonal a ...... and intra-tumor accumulation.

@en

Agonist anti-GITR monoclonal a ...... and intra-tumor accumulation.

@nl

type

label

Agonist anti-GITR monoclonal a ...... and intra-tumor accumulation.

@ast

Agonist anti-GITR monoclonal a ...... and intra-tumor accumulation.

@en

Agonist anti-GITR monoclonal a ...... and intra-tumor accumulation.

@nl

prefLabel

Agonist anti-GITR monoclonal a ...... and intra-tumor accumulation.

@ast

Agonist anti-GITR monoclonal a ...... and intra-tumor accumulation.

@en

Agonist anti-GITR monoclonal a ...... and intra-tumor accumulation.

@nl

P1433

Q33573450-6C895536-40C2-4CFB-9D68-865C8DA1F396

P1476

Q33573450-4ADDC5C9-61A3-463D-8FA9-747FF4B101E1

P2093

Q33573450-1A73A66B-46C3-431E-A023-A6C93A96F6B7

Q33573450-26F8FEEF-23A3-4B90-BDFF-CA9E33F76D78

Q33573450-2BC103DE-06B8-4A6D-8672-8B8681B87B0D

Q33573450-33C28AD0-7745-45F1-9F66-6BF648434C08

Q33573450-4770172B-B608-4109-83CB-4DC9CA557559

Q33573450-55F50BE3-7D90-4645-A8DC-3B4B3BC6D43D

Q33573450-6CE47093-646D-4553-BBDA-511646DF500D

Q33573450-719D9DD3-AFD7-4401-853E-DB760B799BD0

Q33573450-B2CC6EAA-E2CD-4837-9134-06F89E7ED5DB

Q33573450-BBFD0CE9-46E8-4BEF-A61F-F9CA39E32561

P2860

Q33573450-031DEDDD-92A4-4452-9C83-D6D05EDC3AE5

Q33573450-068E7344-7465-4A9F-B3E6-26A8D665BFEE

Q33573450-07D2A899-3074-41A0-A350-8A61F8353C8E

Q33573450-14139101-505A-40E2-8CD5-A10CC1FFA1BE

Q33573450-1414CEFB-700F-4783-B998-A72D3AF1B399

Q33573450-174BEBB8-C25C-4803-B71B-42271EC7EC29

Q33573450-206F0294-C85D-4D9E-AAA1-EEF24D98E898

Q33573450-2267BFED-69C6-45BE-94A7-538640F2C4BB

Q33573450-272BAB82-E95B-4286-978A-325F08008D55

Q33573450-33746DD4-4785-400E-BD77-FBAE8D5F7B7E

P304

Q33573450-7326F22B-2117-451B-9135-88C60ACD5D79

P31

Q33573450-1B50591F-1CB4-4B73-8F1B-129AE87F49A6

P356

Q33573450-8CE6D103-5FCE-4CD3-A9C9-B6C9EE96A9E6

P407

Q33573450-9980C6B2-519D-407D-9067-79AFDCCC5E6C

P433

Q33573450-84699E96-F9E4-458E-A4E6-6BE13060AFC8

P478

Q33573450-300B1E91-6DA8-4AF4-85C3-47E274F2A512

P50

Q33573450-905BBBDE-01E5-436C-BA8F-4B70C7FBBDFD

P577

Q33573450-072A8B6D-1C1C-4604-83CD-40196DA1B8E0

P5875

Q33573450-52A9007D-1AE4-4211-A5A7-1D6BB87A841A

P698

Q33573450-8BE97FA9-B346-4F11-8152-971B1DC6D276

P921

Q33573450-AABCB47E-EEB0-4D41-839E-CD082670AF2A

P932

Q33573450-26DDF8AF-3192-4B33-82E9-B4353312790C

P356

JOURNAL.PONE.0010436

P1433

P1476

Agonist anti-GITR monoclonal a ...... and intra-tumor accumulation.

@en

P2093

Adi Diab

http://www.w3.org/2001/XMLSchema#string

Alan N Houghton

http://www.w3.org/2001/XMLSchema#string

Cailian Liu

http://www.w3.org/2001/XMLSchema#string

Daniel Hirschhorn-Cymmerman

http://www.w3.org/2001/XMLSchema#string

David A Schaer

http://www.w3.org/2001/XMLSchema#string

Fei Duan

http://www.w3.org/2001/XMLSchema#string

Gabrielle Rizzuto

http://www.w3.org/2001/XMLSchema#string

Jedd D Wolchok

http://www.w3.org/2001/XMLSchema#string

Miguel A Perales

http://www.w3.org/2001/XMLSchema#string

Soo Chong Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Regulatory T cell lineage specification by the forkhead transcription factor foxp3

Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

How regulatory T cells work

Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis

In vivo kinetics of GITR and GITR ligand expression and their functional significance in regulating viral immunopathology.

Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance.

CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor.

Role of GITR in activation response of T lymphocytes.

GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations.

P304

e10436

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0010436

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-05-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44584663

http://www.w3.org/2001/XMLSchema#string

P698

20454651

http://www.w3.org/2001/XMLSchema#string

P921

P932

2862699

http://www.w3.org/2001/XMLSchema#string